BACKGROUND: This retrospective real-world study used data from two registries, International Pediatric Peritoneal Dialysis Network (IPPN) and International Pediatric Hemodialysis Network (IPHN), to characterize the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) in pediatric patients with chronic kidney disease (CKD) on peritoneal dialysis (PD) or hemodialysis (HD). METHODS: IPPN and IPHN collect prospective data (baseline and every 6 months) from pediatric PD and HD centers worldwide. Demographics, clinical characteristics, dialysis information, treatment, laboratory parameters, number and causes of hospitalization events, and deaths were extracted for patients on C.E.R.A. treatment (IPPN: 2007-2021; IPHN: 2013-2021). RESULTS: We analyzed 177 patients on PD (median age 10.6 years) and 52 patients on HD (median age 14.1 years) who had ≥ 1 observation while being treated with C.E.R.A. The median (interquartile range [IQR]) observation time under C.E.R.A. exposure was 6 (0-12.5) and 12 (0-18) months, respectively. Hemoglobin concentrations were stable over time; respective means (standard deviation) at last observation were 10.9 (1.7) g/dL and 10.4 (1.7) g/dL. Respective median (IQR) monthly C.E.R.A. doses at last observation were 3.5 (2.3-5.1) µg/kg, or 95 (62-145) µg/m2 and 2.1 (1.2-3.4) µg/kg, or 63 (40-98) µg/m2. Non-elective hospitalizations occurred in 102 (58%) PD and 32 (62%) HD patients. Seven deaths occurred (19.8 deaths per 1000 observation years). CONCLUSIONS: C.E.R.A. was associated with efficient maintenance of hemoglobin concentrations in pediatric patients with CKD on dialysis, and appeared to have a favorable safety profile. The current analysis revealed no safety signals.

Department of Paediatrics Yong Loo Lin School of Medicine National University of Singapore Singapore Republic of Singapore

Department of Pediatrics and Transplantation Center University Hospital Motol 2nd Medical Faculty Prague Charles University Prague Prague Czech Republic

Division of Pediatric Nephrology Center for Pediatrics and Adolescent Medicine Heidelberg Germany

Division of Pediatric Nephrology Children's Mercy Kansas City Kansas City MO USA

Division of Pediatric Nephrology Hospital Dr Luis Calvo Mackenna Facultad de Medicina Universidad de Chile Santiago Chile

Division of Pediatric Nephrology Hospital Italiano de Buenos Aires Buenos Aires Argentina

F Hoffmann La Roche Ltd Basel Switzerland

Institute of Medical Biometry University of Heidelberg Heidelberg Germany

Zobrazit více v PubMed

Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: Prevalence and predictors. Pediatr Nephrol. 2000;14:898–902. doi: 10.1007/s004670000303. PubMed DOI

Chavers BM, Herzog CA. The spectrum of cardiovascular disease in children with predialysis chronic kidney disease. Adv Chronic Kidney Dis. 2004;11:319–327. doi: 10.1053/j.arrt.2004.04.002. PubMed DOI

Sietsema KE, Hiatt WR, Esler A, Adler S, Amato A, Brass EP. Clinical and demographic predictors of exercise capacity in end-stage renal disease. Am J Kidney Dis. 2002;39:76–85. doi: 10.1053/ajkd.2002.29884. PubMed DOI

Pattaragarn A, Warady BA, Sabath RJ. Exercise capacity in pediatric patients with end-stage renal disease. Perit Dial Int. 2004;24:274–280. doi: 10.1177/089686080402400310. PubMed DOI

Klang B, Björvell H, Clyne N. Quality of life in predialytic uremic patients. Qual Life Res. 1996;5:109–116. doi: 10.1007/bf00435975. PubMed DOI

Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis. 2004;44:1017–1023. doi: 10.1053/j.ajkd.2004.08.024. PubMed DOI

Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619. doi: 10.1681/asn.V103610. PubMed DOI

Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309–1316. doi: 10.1681/asn.V1061309. PubMed DOI

Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 2003;18:1055–1062. doi: 10.1007/s00467-003-1214-1. PubMed DOI

Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F. Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD. Clin J Am Soc Nephrol. 2018;13:81–90. doi: 10.2215/CJN.03570417. PubMed DOI PMC

U.S. National Library of Medicine (2022) Ascertain the optimal starting dose of Mircera given subcutaneously for maintenance treatment of anemia in pediatric patients with chronic kidney disease on dialysis or not yet on dialysis. https://clinicaltrials.gov/ct2/show/NCT03552393. Accessed May 2022

Warady BA, Meyer Reigner S, Tirodkar C, Drozdz D (2022) Subcutaneous C.E.R.A. for the maintenance treatment of anemia in pediatric patients with CKD: a phase 2, open-label, single-arm, multicenter study. Am J Kidney Dis. 10.1053/j.ajkd.2022.11.006 PubMed

International Pediatric Dialysis Network (IPDN) About IPDN. http://www.pedpd.org/index.php?id=14. Accessed May 2022

Vifor (International) Inc. (2022) MIRCERA® (methoxy polyethylene glycol-epoetin beta). Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125164s086lbl.pdf. Accessed 12 Dec 2022

Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics. 2010;2:389–418. doi: 10.3390/pharmaceutics2040389. PubMed DOI PMC

Port RE, Mehls O. Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? Pediatr Nephrol. 2009;24:435–437. doi: 10.1007/s00467-008-0955-2. PubMed DOI

Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Müller-Wiefel DE, Sander A, Warady BA, Schaefer F; International Pediatric Peritoneal Dialysis Network (IPPN) registry (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665–676. 10.1681/asn.2012050433 PubMed PMC

Borzych-Duzalka D, Shroff R, Ariceta G, Yap YC, Paglialonga F, Xu H, Kang HG, Thumfart J, Aysun KB, Stefanidis CJ, Fila M, Sever L, Vondrak K, Szabo AJ, Szczepanska M, Ranchin B, Holtta T, Zaloszyc A, Bilge I, Warady BA, Schaefer F, Schmitt CP. Vascular access choice, complications, and outcomes in children on maintenance hemodialysis: Findings from the international pediatric hemodialysis network (IPHN) registry. Am J Kidney Dis. 2019;74:193–202. doi: 10.1053/j.ajkd.2019.02.014. PubMed DOI

Ploos van Amstel S, Noordzij M, Borzych-Duzalka D, Chesnaye NC, Xu H, Rees L, Ha IS, Antonio ZL, Hooman N, Wong W, Vondrak K, Yap YC, Patel H, Szczepanska M, Testa S, Galanti M, Kari JA, Samaille C, Bakkaloglu SA, Lai WM, Rojas LF, Diaz MS, Basu B, Neu A, Warady BA, Jager KJ, Schaefer F. Mortality in children treated with maintenance peritoneal dialysis: Findings from the International Pediatric Peritoneal Dialysis Network Registry. Am J Kidney Dis. 2021;78:380–390. doi: 10.1053/j.ajkd.2020.11.031. PubMed DOI